Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 38542194)

  • 21. Probabilistic colocalization of genetic variants from complex and molecular traits: promise and limitations.
    Hukku A; Pividori M; Luca F; Pique-Regi R; Im HK; Wen X
    Am J Hum Genet; 2021 Jan; 108(1):25-35. PubMed ID: 33308443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrence Risk after Radical Colorectal Cancer Surgery-Less Than before, But How High Is It?
    Osterman E; Hammarström K; Imam I; Osterlund E; Sjöblom T; Glimelius B
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33182510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AURKA Increase the Chemosensitivity of Colon Cancer Cells to Oxaliplatin by Inhibiting the TP53-Mediated DNA Damage Response Genes.
    Shan B; Zhao R; Zhou J; Zhang M; Qi X; Wang T; Gong J; Wu Y; Zhu Y; Yang W; Zhang Y; Wang G; Li X
    Biomed Res Int; 2020; 2020():8916729. PubMed ID: 32851091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
    Dasari A; Morris VK; Allegra CJ; Atreya C; Benson AB; Boland P; Chung K; Copur MS; Corcoran RB; Deming DA; Dwyer A; Diehn M; Eng C; George TJ; Gollub MJ; Goodwin RA; Hamilton SR; Hechtman JF; Hochster H; Hong TS; Innocenti F; Iqbal A; Jacobs SA; Kennecke HF; Lee JJ; Lieu CH; Lenz HJ; Lindwasser OW; Montagut C; Odisio B; Ou FS; Porter L; Raghav K; Schrag D; Scott AJ; Shi Q; Strickler JH; Venook A; Yaeger R; Yothers G; You YN; Zell JA; Kopetz S
    Nat Rev Clin Oncol; 2020 Dec; 17(12):757-770. PubMed ID: 32632268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: Real-world data from a large cohort of older adults.
    Weiser E; Parks PD; Swartz RK; Thomme JV; Lavin PT; Limburg P; Berger BM
    J Med Screen; 2021 Mar; 28(1):18-24. PubMed ID: 32054393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer.
    Kim SK; Kim SY; Kim CW; Roh SA; Ha YJ; Lee JL; Heo H; Cho DH; Lee JS; Kim YS; Kim JC
    Exp Mol Med; 2019 Oct; 51(10):1-12. PubMed ID: 31578316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploratory Data Mining for Subgroup Cohort Discoveries and Prioritization.
    Liu D; Baskett W; Beversdorf D; Shyu CR
    IEEE J Biomed Health Inform; 2020 May; 24(5):1456-1468. PubMed ID: 31494566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Immunoscore: Colon Cancer and Beyond.
    Angell HK; Bruni D; Barrett JC; Herbst R; Galon J
    Clin Cancer Res; 2020 Jan; 26(2):332-339. PubMed ID: 31413009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
    Wu HX; Wang ZX; Zhao Q; Wang F; Xu RH
    J Immunother Cancer; 2019 Aug; 7(1):206. PubMed ID: 31387639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel prognostic prediction model for recurrence in patients with stage II colon cancer after curative resection.
    Saso K; Myoshi N; Fujino S; Takenaka Y; Takahashi Y; Nishimura J; Yasui M; Ohue M; Tokuoka M; Ide Y; Takahashi H; Haraguchi N; Hata T; Matsuda C; Mizushima T; Doki Y; Mori M
    Mol Clin Oncol; 2018 Dec; 9(6):697-701. PubMed ID: 30546904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.
    Allen WL; Dunne PD; McDade S; Scanlon E; Loughrey M; Coleman H; McCann C; McLaughlin K; Nemeth Z; Syed N; Jithesh P; Arthur K; Wilson R; Coyle V; McArt D; Murray GI; Samuel L; Nuciforo P; Jimenez J; Argiles G; Dienstmann R; Tabernero J; Messerini L; Nobili S; Mini E; Sheahan K; Ryan E; Johnston PG; Van Schaeybroeck S; Lawler M; Longley DB
    JCO Precis Oncol; 2018 Jun; 2018():. PubMed ID: 30088816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncologist use and perception of large panel next-generation tumor sequencing.
    Schram AM; Reales D; Galle J; Cambria R; Durany R; Feldman D; Sherman E; Rosenberg J; D'Andrea G; Baxi S; Janjigian Y; Tap W; Dickler M; Baselga J; Taylor BS; Chakravarty D; Gao J; Schultz N; Solit DB; Berger MF; Hyman DM
    Ann Oncol; 2017 Sep; 28(9):2298-2304. PubMed ID: 28911072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive models of adjuvant chemotherapy for patients with stage ii colorectal cancer: A retrospective study.
    Wei B; Zheng XM; Lei PR; Huang Y; Zheng ZH; Chen TF; Huang JL; Fang JF; Liang CH; Wei HB
    Chin Med J (Engl); 2017 Sep; 130(17):2069-2075. PubMed ID: 28836550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AACR Project GENIE: Powering Precision Medicine through an International Consortium.
    AACR Project GENIE Consortium
    Cancer Discov; 2017 Aug; 7(8):818-831. PubMed ID: 28572459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.
    Rankin A; Klempner SJ; Erlich R; Sun JX; Grothey A; Fakih M; George TJ; Lee J; Ross JS; Stephens PJ; Miller VA; Ali SM; Schrock AB
    Oncologist; 2016 Nov; 21(11):1306-1314. PubMed ID: 27682134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.
    Schell MJ; Yang M; Teer JK; Lo FY; Madan A; Coppola D; Monteiro AN; Nebozhyn MV; Yue B; Loboda A; Bien-Willner GA; Greenawalt DM; Yeatman TJ
    Nat Commun; 2016 Jun; 7():11743. PubMed ID: 27302369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of recurrence free survival for patients with stage II and III colon cancer.
    Tsikitis VL; Larson DW; Huebner M; Lohse CM; Thompson PA
    BMC Cancer; 2014 May; 14():336. PubMed ID: 24886281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Random survival forests for competing risks.
    Ishwaran H; Gerds TA; Kogalur UB; Moore RD; Gange SJ; Lau BM
    Biostatistics; 2014 Oct; 15(4):757-73. PubMed ID: 24728979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
    Gao J; Aksoy BA; Dogrusoz U; Dresdner G; Gross B; Sumer SO; Sun Y; Jacobsen A; Sinha R; Larsson E; Cerami E; Sander C; Schultz N
    Sci Signal; 2013 Apr; 6(269):pl1. PubMed ID: 23550210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.